Cambridge Healthtech Institute’s 6th Annual
Oncolytic Virus Immunotherapy
October 5-6, 2021
The use of oncolytic viruses has expanded rapidly over the past five years with interest in the field at an all-time high following recent scientific breakthroughs and multi-million dollar investments from big pharma. Cambridge Healthtech Institute’s
6th Annual Oncolytic Virus Immunotherapy conference brings together leading academics, clinicians and industry experts to discuss the latest developments in oncolytic virotherapy and the steps needed to accelerate product development
- from virus engineering to new mechanisms of action; combinations to major clinical updates; delivery to commercialization.
Coverage will include, but is not limited to:
Latest updates and Future Directions in Oncolytic Virus Immunotherapy
- Future direction in oncolytic virotherapy
- Feedback from big pharma –where does OV sit in big pharma IO portfolios, long term position
- What needs to happen to take OVs forward
- Update from companies with late-stage products/approvals – post market approvals
Improving OV Potency, Targeting and Efficacy
- Engineering strategies to improve efficacy and specificity – highly armed OVs
- New virus, mechanism of actions
- Tumor targeted delivery
- Impact of Tumor Microenvironment
Oncolytics in Development: Update on Major Clinical and Preclinical Therapies
- Clinical updates – results, safety, efficacy issues, patient selection, setting endpoints, presenting data to physicians
- Lessons learnt in the clinic – translational strategies, novel preclinical models biomarkers
- Regulatory expectations –what to submit to regulators, data to include, feedback
- Commercialization and manufacturing strategies
Oncolytics in an Era of Combination Therapies
- Are combinations the only way forward for oncolytics?
- Examples of successful combination models – checkpoints, CAR Ts, kinase inhibitors, alternative to checkpoints, antibodies
- Issues when combining OVs – feedback on trials
- Evidence to support role of oncolytics as monotherapies?
Improving Delivery and Administration
- Oncolytics as a single shot vs. multiple shots – mechanisms of action. Evidence-based medicine
- IV vs. systemic - dosage, delivery, delivery when combining with PD-1s
- Evidence to support systemic route, what data is available
CMC, Manufacturing and Commercialization
- Interactions and experience with regulators
- Scale up and manufacturing strategies for oncolytic viruses
- Pricing and commercialization strategies
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is April 9, 2021.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+44) 7837 651 303
For partnering and sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286